Chemed (CHE) Competitors $447.32 +5.08 (+1.15%) Closing price 03:59 PM EasternExtended Trading$443.72 -3.60 (-0.80%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHE vs. MEDP, LH, DGX, DVA, CRVL, AMED, MD, AMN, CCRN, and EHCShould you be buying Chemed stock or one of its competitors? The main competitors of Chemed include Medpace (MEDP), Labcorp (LH), Quest Diagnostics (DGX), DaVita (DVA), CorVel (CRVL), Amedisys (AMED), Pediatrix Medical Group (MD), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), and Encompass Health (EHC). Chemed vs. Its Competitors Medpace Labcorp Quest Diagnostics DaVita CorVel Amedisys Pediatrix Medical Group AMN Healthcare Services Cross Country Healthcare Encompass Health Medpace (NASDAQ:MEDP) and Chemed (NYSE:CHE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations. Which has preferable valuation and earnings, MEDP or CHE? Medpace has higher earnings, but lower revenue than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedpace$2.11B6.54$404.39M$13.4536.49Chemed$2.43B2.68$302M$19.4523.00 Which has more risk and volatility, MEDP or CHE? Medpace has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Chemed has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Is MEDP or CHE more profitable? Medpace has a net margin of 18.74% compared to Chemed's net margin of 11.56%. Medpace's return on equity of 67.66% beat Chemed's return on equity.Company Net Margins Return on Equity Return on Assets Medpace18.74% 67.66% 21.86% Chemed 11.56%25.83%17.77% Do analysts recommend MEDP or CHE? Medpace currently has a consensus target price of $422.27, suggesting a potential downside of 13.96%. Chemed has a consensus target price of $578.50, suggesting a potential upside of 29.33%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than Medpace.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medpace 3 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.94Chemed 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer MEDP or CHE? In the previous week, Medpace had 1 more articles in the media than Chemed. MarketBeat recorded 22 mentions for Medpace and 21 mentions for Chemed. Medpace's average media sentiment score of 1.27 beat Chemed's score of 1.17 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 16 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 14 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in MEDP or CHE? 78.0% of Medpace shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 20.3% of Medpace shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryMedpace beats Chemed on 10 of the 16 factors compared between the two stocks. Get Chemed News Delivered to You Automatically Sign up to receive the latest news and ratings for CHE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHE vs. The Competition Export to ExcelMetricChemedMED IndustryMedical SectorNYSE ExchangeMarket Cap$6.52B$5.39B$5.69B$21.37BDividend Yield0.54%1.28%5.72%3.49%P/E Ratio23.0028.6075.8629.83Price / Sales2.68162.97489.9288.60Price / Cash17.3626.8725.8118.13Price / Book6.024.4612.844.58Net Income$302M$189.47M$3.28B$998.53M7 Day Performance-3.37%-2.58%0.22%1.07%1 Month Performance0.52%1.63%4.61%4.41%1 Year Performance-22.74%13.58%68.33%14.45% Chemed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHEChemed4.9986 of 5 stars$447.32+1.1%$578.50+29.3%-23.0%$6.44B$2.43B21.5815,695Positive NewsShort Interest ↓MEDPMedpace4.308 of 5 stars$492.09+1.0%$412.73-16.1%+41.2%$13.68B$2.11B36.595,900Positive NewsLHLabcorp4.6494 of 5 stars$276.99-0.6%$290.33+4.8%+24.5%$23.16B$13.01B30.5770,000Positive NewsDGXQuest Diagnostics4.7736 of 5 stars$182.53-0.5%$186.00+1.9%+17.1%$20.52B$9.87B21.8656,000Positive NewsDVADaVita4.6494 of 5 stars$134.44-2.5%$164.00+22.0%-19.9%$9.86B$12.82B13.2276,000Analyst UpgradeCRVLCorVel2.0573 of 5 stars$90.34+5.7%N/A-21.6%$4.39B$918.58M46.575,075High Trading VolumeAMEDAmedisys2.0446 of 5 stars$101.01+0.0%$100.50-0.5%+4.2%$3.32B$2.40B39.3020,000MDPediatrix Medical Group2.3479 of 5 stars$16.95-0.7%$16.79-1.0%+51.5%$1.49B$2.01B13.144,305Analyst DowngradeAMNAMN Healthcare Services4.6292 of 5 stars$20.97+0.6%$28.25+34.7%-61.4%$799.06M$2.98B-2.702,968Short Interest ↓CCRNCross Country Healthcare3.5862 of 5 stars$14.05-0.4%$17.93+27.6%-7.1%$461.94M$1.34B-54.048,205Positive NewsEHCEncompass Health4.8023 of 5 stars$125.93+0.3%$134.00+6.4%+33.6%$12.65B$5.37B24.6440,000Positive NewsAnalyst ForecastShort Interest ↑ Related Companies and Tools Related Companies Medpace Alternatives Labcorp Alternatives Quest Diagnostics Alternatives DaVita Alternatives CorVel Alternatives Amedisys Alternatives Pediatrix Medical Group Alternatives AMN Healthcare Services Alternatives Cross Country Healthcare Alternatives Encompass Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CHE) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemed Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
